March 11, 2009 -- Schering-Plough Corporation today announced that the U.S. FDA has approved new labeling for PEGINTRON (peginterferon alfa-2b) and REBETOL (ribavirin, USP) combination therapy for treating chronic hepatitis C in patients 3 years of age and older with compensated liver disease. With approval of this expanded indication, PEGINTRON and REBETOL is the first and only pegylated interferon combination therapy approved in the United States that is not restricted to treatment-naive patients.
The details can be read here.
No comments:
Post a Comment